Zoni Berisso M, Carratino L, De Caro E, Ferroni A, Vecchio C
G Ital Cardiol. 1987 Mar;17(3):233-8.
A placebo-controlled single-blind study was performed to evaluate the efficacy of oral propafenone on stable potentially malignant ventricular tachyarrhythmias in 13 patients who had suffered a myocardial infarction two months or longer before the trial. All patients exhibited at a 24 hour Holter monitoring a minimum mean frequency of 10 ventricular premature depolarizations (VPDs) per hour and repetitive VPDs. Ventricular tachyarrhythmias characterization was obtained by means of multiple Holter monitorings and exercise stress testings. Propafenone was considered as effective when a well-defined quantitative and qualitative reduction of ventricular tachyarrhythmias was reached. After an initial placebo phase, patients received propafenone 450 mg or 900 mg daily. Acute effectiveness of propafenone was proved in 8 on 13 patients (62%) who showed a significative reduction of VPDs (89%, p less than 0.02) and a suppression of the most complex forms of ventricular tachyarrhythmic events. The efficacy of propafenone was confirmed, three months later, in each patient, side effects were infrequent, minimal and of no clinical consequence. Oral propafenone can be considered as an effective drug for reducing the level of potentially malignant ventricular tachyarrhythmias in patients with previous myocardial infarction.
进行了一项安慰剂对照单盲研究，以评估口服普罗帕酮对13例在试验前两个月或更长时间发生过心肌梗死的患者的稳定的潜在恶性室性心律失常的疗效。所有患者在24小时动态心电图监测中均表现出每小时至少10次室性早搏（VPD）的平均频率以及重复性VPD。通过多次动态心电图监测和运动负荷试验对室性心律失常进行特征描述。当室性心律失常在定量和定性方面有明确的减少时，普罗帕酮被认为是有效的。在初始安慰剂阶段后，患者接受每日450毫克或900毫克的普罗帕酮治疗。13例患者中有8例（62%）证明普罗帕酮有急性疗效，这些患者的VPD有显著减少（89%，p<0.02），并且最复杂形式的室性心律失常事件得到抑制。三个月后，每位患者普罗帕酮的疗效均得到证实，副作用很少，程度轻微且无临床后果。口服普罗帕酮可被认为是一种有效药物，用于降低既往有心肌梗死患者的潜在恶性室性心律失常水平。
